Video
Dr. Choueiri on CABOSUN Trial Results for RCC
Author(s):
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the results of the phase II CABOSUN trial, which compared cabozantinib (Cabometyx) with sunitinib (Sutent) in the frontline setting of patients with metastatic renal cell carcinoma (RCC).
Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, discusses the results of the phase II CABOSUN trial, which compared cabozantinib (Cabometyx) with sunitinib (Sutent) in the frontline setting of patients with metastatic renal cell carcinoma (RCC).
This trial asks an important question: whether cabozantinib is superior to sunitinib, which is the standard of care for this patient population in the frontline setting. Prior trial data show that in the second-line setting, cabozantinib improves clinical outcomes compared with everolimus (Afinitor).
Results of the CABOSUN trial showed that cabozantinib did show a statistically significant improvement in progression-free survival in patients compared with sunitinib.
